HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
用户4KhrZdZ8V8-Y
1个月前
44
10
已完结
1. 系统已在2025-07-23 17:06:37对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1158/1535-7163.MCT-21-0835
其他信息:
出版社: American Association for Cancer Research (AACR)
作者: Yong Du; Yongfeng Chen; Yuxia Wang; Jinju Chen; Xiaorong Lu; Li Zhang; Yan Li; Zhaofu Wang; Guozhong Ye; George Zhang
全文下载地址: https://aacrjournals.org/mct/article-pdf/doi/10.1158/1535-7163.MCT-21-0835/3126949/mct-21-0835.pdf
